What is the safest antidepressant for an elderly female patient with a history of hyponatremia?

Safest Antidepressant for Elderly Female with History of Hyponatremia

Bupropion is the safest antidepressant choice for an elderly female patient with a history of hyponatremia, as it has the lowest association with hyponatremia among all antidepressants due to its unique dopaminergic/noradrenergic mechanism that does not affect serotonin.

Primary Recommendation

Start with bupropion (Wellbutrin) at a reduced dose (approximately 50% of standard adult starting dose) given the patient's age and monitor closely. 1, 2

Why Bupropion?

• Lowest hyponatremia risk: Bupropion was implicated far less frequently in hyponatremia cases compared to SSRIs, SNRIs, and mirtazapine in comprehensive literature reviews 2
• Unique mechanism: Its dopaminergic/noradrenergic action without serotonergic effects makes it mechanistically distinct from drugs that cause hyponatremia 2
• Guideline-supported: Listed as a preferred agent for older adults with favorable adverse effect profile 1

Alternative Options (If Bupropion Contraindicated)

If bupropion is not suitable (e.g., seizure history, eating disorder), consider these alternatives in order of preference:

Second Choice: Mirtazapine

• Conflicting evidence exists: Some data suggests lower risk compared to SSRIs 3, 4, but other pharmacovigilance data shows mirtazapine had the highest reporting odds ratio for hyponatremia among antidepressants 5
• The 2026 meta-analysis found mirtazapine associated with significantly lower risk (RR = 0.49-0.61) compared to SSRIs 3
• However, a 2018 FAERS database analysis found mirtazapine had the strongest association with hyponatremia 5
• Clinical caveat: This contradiction likely reflects confounding by indication—mirtazapine may be preferentially prescribed to patients already at higher baseline risk for hyponatremia 5

Third Choice: Tricyclic Antidepressants (Secondary Amines Only)

• Nortriptyline or desipramine have lower hyponatremia risk than SSRIs/SNRIs 2, 4
• Adjusted OR for hyponatremia was only 1.59 for TCAs versus 4.96-5.50 for SSRIs 4
• Must use secondary-amine TCAs (nortriptyline, desipramine)—NOT tertiary-amine TCAs (amitriptyline, imipramine) which are potentially inappropriate per Beers Criteria due to anticholinergic effects 6, 1

Antidepressants to AVOID

Do NOT use the following in this patient:

Absolutely Contraindicated:

• SSRIs (especially citalopram, escitalopram, sertraline): Event rates of 9.8-10.4% for any hyponatremia; adjusted OR 4.96-5.50 for hospitalization 3, 4
• SNRIs (venlafaxine, duloxetine): Highest risk class with event rate of 10.4% and adjusted OR 5.28 for hospitalization 3, 4
• Paroxetine and fluoxetine: Should be avoided in older adults regardless due to anticholinergic effects and agitation risk 1

Critical Timing Information:

• Peak risk occurs in first 2 weeks: Adjusted OR of 10.06 during first 14 days after SSRI/SNRI initiation 7
• Risk remains elevated for first 3 months (aOR 4.29), then decreases substantially 7
• Among women ≥80 years, 1 in 15 will develop profound hyponatremia with SSRIs/SNRIs 7

Monitoring Protocol

If you must use an SSRI/SNRI despite the history (not recommended):

1. Baseline sodium before starting
2. Check sodium at 1-2 weeks (highest risk period) 7
3. Recheck at 1 month and 3 months 8
4. Educate patient on symptoms: confusion, nausea, headache, lethargy

Risk Factors That Increase Hyponatremia Risk:

• Female gender (significantly higher risk) 8, 7
• Age ≥80 years (6.5% incidence in women) 7
• Concomitant medications: diuretics, NSAIDs, ACE inhibitors/ARBs with TMP-SMX 6
• Malignancy, diabetes mellitus 9

Key Evidence Summary

The 2026 meta-analysis of 2.1 million geriatric patients found 3:

• SNRIs: Highest event rate (10.4% any hyponatremia, 5.0% clinically relevant)
• SSRIs: Second highest (9.8% any hyponatremia, 2.8% clinically relevant)
• Mirtazapine: Lower risk than SSRIs (RR 0.49-0.61)
• Absolute risk increase: 0.37-0.46% compared to non-users

The 2018 Swedish register study of 14,359 hyponatremia hospitalizations showed 4:

• Newly initiated SSRIs/venlafaxine had adjusted ORs of 4.96-5.50
• TCAs had adjusted OR of only 1.59
• No increased risk with ongoing treatment (>3 months)

Clinical Bottom Line

Prescribe bupropion as first-line for this patient. If absolutely necessary to use a serotonergic antidepressant, secondary-amine TCAs (nortriptyline) carry lower risk than SSRIs/SNRIs. Avoid all SSRIs and SNRIs given her history. The Beers Criteria note that tramadol was added to drugs associated with hyponatremia/SIADH, so avoid this analgesic as well 6.